Adnexus Files for IPO

Adnexus Therapeutics Inc., a Waltham, Mass.-based developer of therapeutic proteins, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol ADNX, with Lehman Brothers and UBS serving as co-lead underwriters. The company has raised $70 million in total VC funding since 2003, from Atlas Venture, Flagship Ventures, HBM BioVentures, Polaris Venture Partners and Venrock.